Huixin Medical Valley focuses on creating cell-based therapeutics for neurological disorders using its proprietary, internationally leading induced neural stem cell (iNSC) technology. Its pipeline spans multiple central nervous system indications, anchored by an iNSC-derived dopaminergic neural precursor (iNSC-DAP) injection that targets Parkinson’s disease. In a first-in-China, nationally filed clinical study at Xuanwu Hospital, the iNSC-DAP therapy has shown more than two years of follow-up data with sustained improvements in “on/off” time, MDS-UPDRS scores, and imaging readouts, while maintaining a favorable safety profile. The company positions this data as proof of clinical feasibility and a competitive differentiator. Newly raised capital will fund further clinical research and speed the transition of its therapies from bench to bedside and industrial scale. Investors cite the breadth of its pipeline, sound clinical data, and clear development path as reasons for their support. Although the company has not publicly disclosed revenue or user figures, it is regarded as a state-level high-tech enterprise and is entering a critical expansion phase.

Total raised

$14M

Funding rounds

3

Latest round

Series A

Latest activity

Jan 2026